Vividion Therapeutics Files for IPO
Vividion Therapeutics Inc., a biotechnology company that seeks to develop drugs for cancer and immune disorders using "traditionally undruggable targets," filed for an initial public offering.
In its filing, the San Diego company said its technology "addresses the key limitations of conventional screening techniques and allows us to discover previously unknown, or cryptic, functional pockets on the surface of proteins and identify small molecules that selectively bind to those targets."
Vividion said in February that it raised $135 million of Series C financing, co-led by Logos Capital and Boxer Capital of Tavistock Group. The company's investors include ARCH Venture Partners, Versant Ventures and Cardinal Partners. The company has applied for Nasdaq Global Market listing under symbol "VVID."